Elanco Animal Health Stock Price, News & Analysis

Elanco (NYSE: ELAN) announced management will participate in two investor conferences in early December 2025. Jeff Simmons, president and CEO, will appear in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 12:30 p.m. ET. Bob VanHimbergen, EVP and CFO, and Bobby Modi, EVP, US Pet Health and Global Digital Transformation, will appear at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 8:30 a.m. ET. Live audio webcasts and limited-time replays will be available in the company’s Events and Presentations investor website section.

Alloy Partners and Elanco (NYSE: ELAN) launched OneHealth Studio on November 13, 2025, a venture studio in the OneHealth Innovation District at Elanco's new global headquarters in Indianapolis.

The studio will convene research institutions, investors, corporate partners and entrepreneurs to create and scale startups at the convergence of animal, plant and human health. The State of Indiana will provide support with matching federal SSBCI funds. Alloy will operate the studio using its venture-studio model and plans to launch and fund startups over the next few years while adding corporate and institutional partners.

Elanco (NYSE: ELAN) reported Q3 2025 revenue of $1,137 million, up 10% year‑over‑year (9% organic CC). Adjusted EBITDA was $198 million (17.5% margin) and adjusted net income was $94 million (adjusted EPS $0.19).

The company raised full‑year 2025 guidance to $4,645–$4,670 million revenue, lifted the innovation revenue midpoint by $100 million to a range of $840–$880 million, raised adjusted EBITDA to $880–$900 million, and improved year‑end net leverage target to 3.7x–3.8x.

Elanco (NYSE: ELAN) announced U.S. label expansions for Credelio Quattro and Credelio on Oct 27, 2025, adding prevention of Lyme disease via killing black-legged ticks (Ixodes scapularis) and treatment/control of the invasive longhorned tick (Haemaphysalis longicornis).

The labels reflect clinical evidence, including a peer-reviewed study showing 100% efficacy against longhorned tick at 48 hours and data supporting lotilaner’s rapid tick kill versus competing products. The announcements cite >422,000 canine Lyme cases recorded year-to-date and note longhorned ticks have been detected in 22 states.

Elanco (NYSE: ELAN) received an FDA Emergency Use Authorization (EUA) on October 24, 2025 for Credelio (lotilaner) to treat New World screwworm (NWS) infestations in dogs — the first-ever EUA for NWS in dogs. The EUA follows a peer-reviewed study reporting 100% efficacy against C. hominivorax larvae within 24 hours after oral dosing at the minimum recommended level in 11 naturally infested dogs. The authorization provides a ready treatment option for veterinarians and owners as confirmed NWS cases sit under 70 miles south of the U.S.-Mexico border. Limitations include small sample size, lack of a control group, and uncertain inferential value to U.S. populations.

Elanco (NYSE: ELAN) will host an Investor Day on Tuesday, December 9, 2025, from approximately 9:00 a.m. to 12:00 p.m. ET in New York City.

Senior leadership will present on strategic priorities, financial outlook, and the innovation pipeline. Advance registration is required for in-person attendance; institutional investors and analysts should contact investor@elanco.com. A live webcast, registration details, and presentation materials will be available on Elanco's Investor Events and Presentations website, and a replay will be posted after the event.

Elanco Animal Health (NYSE:ELAN) has scheduled its third quarter 2025 financial results announcement for Wednesday, November 5, 2025. The company will host a conference call at 8:00 a.m. Eastern Time to discuss the quarterly performance with investors, media, and the general public.

A live webcast of the conference call will be accessible through Elanco's investor relations website, with a replay available shortly after the event concludes.

Elanco Animal Health (NYSE:ELAN) announced that the FDA has approved important updates to the U.S. Zenrelia label, removing language about vaccine-induced disease risk. Zenrelia, approved in September 2024, is a once-daily oral JAK inhibitor for controlling itching and inflammation in dogs with skin allergies.

The FDA's decision came after evaluating supplemental scientific data, concluding that "the totality of evidence supports removal of the risk of fatal vaccine-induced disease from modified live virus vaccines from the labeling." The medication has treated over half a million dogs globally, with availability in multiple markets including the EU, Great Britain, Brazil, Japan, and the United States.

The label's Boxed Warning still advises discontinuing Zenrelia for 28 days to 3 months before vaccination and withholding it for at least 28 days after vaccination due to inadequate immune response risks.

Elanco Animal Health (NYSE:ELAN) announced major milestones for two key pet health products. Credelio Quattro achieved blockbuster status with $100 million in net sales in less than eight months, becoming Elanco's fastest pet health blockbuster. The product captured 14% dollar share in broad-spectrum sales at U.S. veterinary clinics in June.

The company also announced the launch of Zenrelia, a once-daily oral JAK inhibitor for treating allergic and atopic dermatitis in dogs, in the EU and Great Britain. The product has already treated over half a million dogs globally and demonstrated non-inferiority versus Apoquel in a study of 338 dogs across 25 sites.